{"filing":{"accession_number":"0001193125-26-342335","cik":"0001831828","ticker":"VERA","company_name":"Vera Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"vera-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/vera-20260810.htm"},"events":[{"id":26527,"run_id":24113,"accession_number":"0001193125-26-342335","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release announcing Vera Therapeutics' second quarter 2026 financial results, including net loss of $109.5 million and net loss per share of $1.52, along with cash position and operating cash flow metrics. The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The material business updates regarding TRUTAKNA's FDA accelerated approval and commercial launch are presented alongside the financial results, making this a comprehensive earnings announcement.","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27681,"accession_number":"0001193125-26-342335","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Vera Therapeutics' second quarter 2026 financial results, including net loss of $109.5 million and net loss per share of $1.52, along with cash position and operating cash flow metrics. The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The material business updates regarding TRUTAKNA's FDA accelerated approval and commercial launch are presented alongside the financial results, making this a comprehensive earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:09:06.858107+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27681,"accession_number":"0001193125-26-342335","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Vera Therapeutics' second quarter 2026 financial results, including net loss of $109.5 million and net loss per share of $1.52, along with cash position and operating cash flow metrics. The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The material business updates regarding TRUTAKNA's FDA accelerated approval and commercial launch are presented alongside the financial results, making this a comprehensive earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:09:06.858107+00:00","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-08-10"}]}